PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50324C00006ANTHIM (obiltoxaximab — Elusys Therapeutics Inc

Elusys Therapeutics Inc holds $123.6M across 5 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2028 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Elusys Therapeutics Inc

Recipient

Dec 31, 2028

PoP end

$124.5M

Obligated

325412

NAICS

6505

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Elusys Therapeutics Inc — $90

Contract facts

NONE

Contract number75A50324C00006

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentElusys Therapeutics Inc

UEIELP1DCK8L191

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Place of performancePARSIPPANY, NJ

PoP end (current)Dec 31, 2028

Obligated$124.5M

ANTHIM (OBILTOXAXIMAB) is a federal NONE award for Aspr/Orm-Sns held by Elusys Therapeutics Inc. Estimated value $124.5M ($124.5M obligated). Current period of performance ends Dec 31, 2028. Last award drew 1 bidder. Place of performance: PARSIPPANY, NJ.

Recompete timing

Public

● Expiring in 846 days

Current PoP ends Dec 31, 2028 (846 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 1, 2027.

Incumbent footprint

Public record

Elusys Therapeutics Inc — $123.6M obligated across 5 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$123.6M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50324C00006?

75A50324C00006 (ANTHIM (obiltoxaximab) is a Aspr/Orm-Sns award with an estimated value of $124.5M, currently held by Elusys Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50324C00006?

Aspr/Orm-Sns awarded 75A50324C00006 to Elusys Therapeutics Inc.

Who is the incumbent on 75A50324C00006?

Elusys Therapeutics Inc is the incumbent with $123.6M across 5 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2028.

When does Elusys Therapeutics Inc’s 75A50324C00006 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50324C00006 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jul 7, 2026